The unusual move at FDA comes shortly after the agency's longtime vaccine chief was forced out over disagreements with Makary ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Novavax's recent performance shows improvement, but significant challenges persist, impacting long-term growth and stability. The company's financials have strengthened due to strategic moves ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax WASHINGTON -- The Trump administration's effort to impose new ...

Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

You can reach Helen on Signal at hbranswell.01. Confusion over the Food and Drug Administration’s delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend when ...

WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is ...